EC Approves Maintenance Lenalidomide for Myeloma

February 24th, 2017 – The European Commission has expanded the indication for lenalidomide to include use as a maintenance therapy for patients with multiple myeloma following autologous hematopoietic stem cell transplant (auto-HSCT), according to Celgene, the manufacturer of the treatment. The approval, which follows a positive opinion from the Committee for Medicinal Products for Human Use, is based on data from from 2 large trials (1000+ patients each) … (leggi tutto)